A Master Protocol (OLMP): A Study of LY4256984 in Participants With Amyotrophic Lateral Sclerosis (ALS)

Recruiting now · Phase 1

Conditions studied: Amyotrophic Lateral Sclerosis

In brief

Study OLMP is a master protocol that will support a collection of individual sub studies that share key design components. Participants from the originator study OWAA (NCT07100119) will be assigned to the appropriate study treatment group: Sporadic Amyotrophic Lateral Sclerosis OL01 (NCT07571174). The studies aim to evaluate the safety and tolerability of different treatments in participants with Amyotrophic Lateral Sclerosis (ALS) that will last at least 96 weeks.

Key facts

Study ID

NCT07571200

Run by

Eli Lilly and Company

People needed

32

Starts

2026-05-14

Expected to finish

2029-06-01

Last updated by the study team

2026-07-17

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Have completed an eligible parent study, as determined by the investigator. Eligible parent studies will be defined by the sponsor but will be clinical studies designed to evaluate a study intervention for the treatment of ALS.
• Note 1: To be considered a "completer" of a parent study, the participant must finish the main treatment period/phase of the parent study as well as any off-treatment period/phase as described in the parent study's protocol.
• Note 2: Visits missed in a parent study will have no impact on the completer status of a potential participant.

You may not qualify if…

• During the parent study, the participant permanently or temporarily discontinued the investigational medicinal product (IMP), such that restarting the IMP would pose an unacceptable risk to the participant's safety, in the opinion of the investigator.
• During the parent study, the participant experienced extreme ALS disease progression (for example, permanent mechanical ventilation) that poses an unacceptable risk to the participant's safety in the opinion of the investigator.
• During the parent study, the participant developed an unresolved SAE or a medical illness (other than ALS) that, in the opinion of the investigator, precludes either continued exposure to an IMP or participation in study procedures due to an unacceptable risk to the participant's safety.

Where it is running

• McGill University Health Centre — Montreal, Canada (enrolling)
• University Hospital - London Health Sciences Centre — London, Canada
• Sunnybrook Research Institute — Toronto, Canada
• Universitätsklinikum Schleswig-Holstein — Lübeck, Germany
• Universitätsmedizin Rostock — Rostock, Germany
• Universitaetsklinikum Ulm — Ulm, Germany
• Universitair Medisch Centrum Utrecht — Utrecht, Netherlands
• Hospital Universitari de Bellvitge — L'Hospitalet de Llobregat, Spain
• UZ Leuven — Leuven, Belgium
• Hospital Universitari i Politecnic La Fe — Valencia, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.